Use of megestrol acetate in advanced breast cancer on a single-daily-dose schedule.

Abstract

Twenty patients with metastatic breast carcinoma received megestrol acetate following additive or ablative therapy. The drug was given in a single oral dose of 160 mg daily to all patients. Side effects and response to therapy appeared comparable to those obtained when the drug is given on a multiple-daily-dose schedule. This small series suggests that megestrol acetate can be used as a single daily dose with comparable therapeutic efficacy and no change in the expected side effects.